MTORC1 MODULATORS Filed on Mar

Total Page:16

File Type:pdf, Size:1020Kb

MTORC1 MODULATORS Filed on Mar US 20190112268A1 ( 19) United States (12 ) Patent Application Publication ( 10) Pub . No. : US 2019 /0112268 A1 Nomura et al . ( 43 ) Pub . Date: Apr . 18 , 2019 ( 54 ) MTORC1 MODULATORS filed on Mar. 6 , 2018, provisional application No . (71 ) Applicant : THE REGENTS OF HE 62/ 572 ,234 , filed on Oct . 13 , 2017 . UNIVERSITY OF CALIFORNIA , Publication Classification Oakland , CA (US ) (51 ) Int. CI. ( 72 ) Inventors : Daniel K . Nomura , Berkeley , CA (US ) ; C07D 209 / 08 (2006 .01 ) Roberto Zoncu , San Francisco , CA A61P 35 / 00 ( 2006 . 01 ) (US ) ; Allison M . Rpberts , Kensington , A61P 25 / 16 ( 2006 . 01) CA (US ) ; Kelvin F . Cho , San A61P 25 / 28 ( 2006 . 01 ) Francisco , CA (US ) ; Yik Sham Clive A61P 3 / 10 (2006 .01 ) Chung , Berkeley, CA (US ) ; Hijai Shin , ( 52 ) U . S . CI. Albany, CA (US ) ; Benjamin Croze, CPC . .. .. C07D 209 /08 ( 2013 .01 ) ; A61P 35 /00 Lafayette , CA (US ) ( 2018 .01 ) ; A61K 47 /64 ( 2017 .08 ) ; A61P 25 / 28 ( 2018 .01 ) ; A61P 3 / 10 (2018 . 01 ) ; A61P 25/ 16 (21 ) Appl . No. : 16 / 159 , 380 (2018 .01 ) ( 22 ) Filed : Oct . 12 , 2018 (57 ) ABSTRACT Provided herein , inter alia , are methods and compounds for Related U . S . Application Data inhibiting mTORC1 and for treating diseases associated ( 60 ) Provisional application No . 62 / 645, 365 , filed on Mar . with mTORC1 activity. 20 , 2018 , provisional application No. 62 /639 ,431 , Specification includes a Sequence Listing . totit drug Patent Application Publication Apr. 18 , 2019 Sheet 1 of 20 US 2019 / 0112268 A1 FIG . IA A ON . WL FIG . 1B FLAG -GFP -RagB FLAG -GFP .Rage FLAG -GFP - RagB W / O FLAG - 3x peptide + 1x FLAG - 3x peptide + 10x FLAG - 3x peptide . .X X . Fluorescence(A.U) Fluorescence(A.U) Fluorescence(A.U) WWW 100 Distance Distance Distance mensPatent Application Publication Apr. 18 ,* 2019 Sheet 2 of 20 US 2019 / 0112268 A1 FIG . IC sonup ** * drugs SA pattidessert... * * ** * WWWME X < FIG . 2A menanamanamanatnamanandaiwanan GFPIRFPratio 295 111111111 wwwwwwwwwwwww www XXX FIG . 2B Patent Application Publication Apr. 18 , 2019 Sheet 3 of 20 US 2019 / 0112268 A1 FIG . 2C mTORCH Lysosomalmembrane FIG . 2D GFP GFP -RAGB + C Cmpd A25 Cmpd A26 YP1- 44 Lamtor DMSO DMSO GFP merge Patent Application Publication Apr. 18 , 2019 Sheet 4 of 20 US 2019 / 0112268 A1 FIG . 2E .• : : TIIIIIIII KO GFP/RFPRatio .177777777777777777TTTTTTTTTTTTTTT MW -1 . DMSOFlag -GFP YP1Compound -44Compound A6 Compound A25 A26 FIG . 2F boundfraction YP1 -44 (nM ) Patent Application Publication Apr . 18 , 2019 Sheet 5 of 20 US 2019 / 0112268 A1 FIG . 3A X siin ' .' . 1 Hun acidsaminoA6wioCompound MTORLamp2 acidsaminoA6Compound* .- mTORLamp2 .- .. Lamp2 RW: YP1-44Woaminoacids mTORLamp2 YP1-44*aminoacids : . DMSOwioaminoacids MTORLamp2 DMSO*aminoacids Lamp2MTOR Patent Application Publication Apr. 18 , 2019 Sheet 6 of 20 US 2019 / 0112268 A1 FIG . 3B FIG .3C 14. Lamp2 LLLLLLLLLL L CompoundA6wloaminoacids $PºEOWLUEOJAT6€¥punodwo zdweVões kikkkkk Ragc !. Lamp2 . 5 Lamp2 YP4-44woaminoacids Ragc Raga Lamp2 SPIOBOULUIBOJAOSWO zd???????14141417 Ragc Patent Application Publication Apr. 18 , 2019 Sheet 7 of 20 US 2019 / 0112268 A1 FIG . 3D . - DMSO option24 * * YP1. -44 500Mma * - - + + - - . ! ! . WO3 . 2 . * . olen amino acids - + - + + S757- : PULK1 ULK1 T3892 . -pS6K1 S6K1 S65 -p4E -BP1 4E - BP1 Patent Application Publication Apr. 18 , 2019 Sheet 8 of 20 US 2019 / 0112268 A1 FIG . 4A . mapping druggable hotspots targetedbycovalentligands . .. heavy:1light . control . , SYCWHIL notinhibited . heavyTEVtag . lightTEVtag . r. Cu-catalyzed . "clickchemistry . Cu-catalyzed . ligand "clickchemistry . lightheavy:3 . peptide1 control . IX . winni YWKDAC*SHR inhibited MS/LC- IsoTOP-ABPPplatformtomapdruggablehotspottargetedbycovalentligands reactivity-based probe reactivity.basedprobe * : ligand 2.avidinenrichment 3.trypticdigestion 4.TEVdigestion covalent WWW control covalentligand treated Patent Application Publication Apr. 18 , 2019 Sheet 9 of 20 US 2019 / 0112268 A1 FIG . 4B ISOTOPwww - ABPP analysis of YP 1 - 44 LAMTOR5 C23 with Ragulator complex QALC DGSAVMFSSK control(light)vs treated(heavy)ratio . LAMTOR5C148 LAMTOR5 C23 FIG . 5A Patent Application PublicationPublication Apr . 18 , 2019 Sheet 10 of 20 US 2019 /0112268 A1 FIG . 5B YP 1 - 44 H3CO H3CO CC 1 - 10 modelsCC 1 - 3 wereCC 1 - 1 OCH3 CC 1 - 14 ageCC 1 - 42 ängeCC 1 - 46 appeCC 1 - 39 mängeCC 1 -44 FIG . 5C (UM ) , DOO LAMTOR5E Patent Application Publication Apr. 18 , 2019 Sheet 11 of 20 US 2019 /0112268 A1 FIG . 5D FIG . 5E . Rapamycin(100nM ) Compounds VSO S AS Torint(250nM ) O wwwwwww * P .SOK w SOK 4EBP Patent Application Publication Apr . 18 , 2019 Sheet 12 of 20 US 2019 /0112268 A1 FIG . 5F 044 * * . *. .. * .. Compounds DMSO 159480 FIG . 6A DMSO YP . 1 - 44 001- 04 . 3 3 :: : : :: : : : : : . : : : . FIG . 6B DMSO [200M ) * AA morge . Patent Application Publication Apr . 18 , 2019 Sheet 13 of 20 US 2019 /0112268 A1 FIG . 6C Lamp2 S MTOR DMSO* AA NO Lamp2 Xx03 :. merge . .: cc - 1 - 44 :. MTOR :. [ 20uM : + AA | : merge FIG . 6D Bafilomycin A1 - - * p62 LC3b Bactin Patent Application Publication Apr . 18 , 2019 Sheet 14 of 20 US 2019 /0112268 A1 FIG . 7A HEART Control cc1- 44 Rapamycin w pS235 / 236 -S6 S6 PT37 /46 -4EBP 4EBP4EBP ????????? PS473 -Akt Akt BODDDDDDDDD Raga SOON . - - . Patent Application Publication Apr . 18 , 2019 Sheet 15 of 20 US 2019 /0112268 A1 FIG . 7B SKELE Control cc1- 44 Rapamycin ?????????? Patent Application Publication Apr . 18 , 2019 Sheet 16 of 20 US 2019 /0112268 A1 FIG . 7C KIDNEY Control 601 -44 Rapamycin AMMA MAAAAAAAAAAAAAAAAAAAAAAAAAAM PS235 / 236 - S6 S6 2 X * * * * * * PS473 - Akt p62 Raga See FIG . 8A . MW Patent Application Publication Apr . 18, 2019 Sheet 17 of 20 US 2019/ 0112268 A1 FIG . 8B 11/UMCC-2 MM 10101 * * * rhodamineazideclickingugCC2-11*complex.)+RagsRagulators(0/ fluorescencegel-In 1001 1001 40 kDa-72 Patent Application Publication Apr . 18 , 2019 Sheet 18 of 20 US 2019 /0112268 A1 FIG . 9A . .* 1 . " * . .. ' · * * * ' : : : t * * . = = = = = = = = = = = = = = = = = = = = = = = = = = = = { ? ? & #2311 # ## 1 Patent Application Publication Apr . 18 , 2019 Sheet 19 of 20 US 2019 /0112268 A1 FIG . 9B ber Y .. Attttt 2 ot * * MWENpereya 2 **** * w th desede of Patent Application Publication Apr . 18 , 2019 Sheet 20 of 20 US 2019 / 0112268 A1 FIG . 9C ? . AAA 20000000 2 2 000 - 100 . ? . US 2019 /0112268 A1 Apr. 18, 2019 MTORC1 MODULATORS - continued (XI ) CROSS - REFERENCES TO RELATED a H APPLICATIONS ( R ? — L ') 21 Or [0001 ] This application claims the benefit of U . S . Provi sional Application No . 62 /572 ,234 , filed Oct. 13 , 2017 ; U . S . ( XXI) Provisional Application No. 62 /639 ,431 , filed Mar. 6 , 2018 ; and U . S . Provisional Application No . 62/ 645 ,365 , filed Mar. 20 , 2018 , which are incorporated herein by reference in their ( R ! — L ') entirety and for all purposes . STATEMENT AS TO RIGHTS TO INVENTIONS [ 0007 ] L is independently a bond , - S ( O ) 2 - , - NH — , MADE UNDER FEDERALLY SPONSORED 0 , S , C ( O ) , LC ( O ) NH , NHC( 0 ) , RESEARCH AND DEVELOPMENT — NHC ( O )NH — , - C ( O ) O - , - OC ( O ) - , substituted or 0002 ] This invention was made with government support unsubstituted alkylene, substituted or unsubstituted het under grants CA172668 and CA195761 awarded by the eroalkylene , substituted or unsubstituted cycloalkylene, sub National Institutes of Health . The government has certain stituted or unsubstituted heterocycloalkylene, substituted or rights in the invention . unsubstituted arylene , or substituted or unsubstituted het eroarylene . REFERENCE TO A “ SEQUENCE LISTING ,” A [ 0008 ] Rl is independently halogen , CX3, CHX ' z, TABLE , OR A COMPUTER PROGRAM LISTING CH , X ' , OCX " z , OCH , XP, OCHX ' , CN , APPENDIX SUBMITTED AS AN ASCII FILE _ SO, R15 , - SONRAR18 , NHC( O ) NRARP, - N ( O ) , NRARIB , C ( O ) RIC , C ( O ) ORIC , [0003 ] The Sequence Listing written in file 052103 C ( O )NRARIB , ORID , - NRASO ,RID , — NR14C ( O ) 511001US _ Sequence _ Listing_ ST25 . txt, created Oct . 12 , RIC, NR14C ( O )ORIC , NRAORIC , N3, substituted 2018 , 24 ,539 bytes , machine format IBM - PC , MS Windows or unsubstituted alkyl , substituted or unsubstituted het operating system , is hereby incorporated by reference . eroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubsti BACKGROUND tuted aryl, or substituted or unsubstituted heteroaryl; two [0004 ] Overwhelming evidence indicates that aberrant adjacent - L - R substituents may optionally be joined to activity of a multiprotein complex known as mechanistic form a substituted or unsubstituted cycloalkyl, substituted or Target of Rapamycin Complex 1 (mTORC1 ) underlies the unsubstituted heterocycloalkyl, substituted or unsubstituted growth advantage that many cancer types display over the aryl , or substituted or unsubstituted heteroaryl. surrounding healthy tissue . Current therapeutic investiga 10009 ) E is an electrophilic moiety . tions in cancer and other mTORC1 - related diseases suffer [0010 ] Each R14 , RIB , RC, and RID is independently from limitations and significant side effects , including high hydrogen , CX3, CHX2, CH X , CN , OH , toxicity and metabolic imbalance . Thus, renewed efforts COOH , CONH2, substituted or unsubstituted alkyl , must be directed toward identifying new ways to block substituted or unsubstituted heteroalkyl, substituted or mTORC1 selectively and safely . Disclosed herein , inter alia , unsubstituted cycloalkyl , substituted or unsubstituted
Recommended publications
  • Proteomics and Drug Repurposing in CLL Towards Precision Medicine
    cancers Review Proteomics and Drug Repurposing in CLL towards Precision Medicine Dimitra Mavridou 1,2,3, Konstantina Psatha 1,2,3,4,* and Michalis Aivaliotis 1,2,3,4,* 1 Laboratory of Biochemistry, School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece; dimitramd@auth.gr 2 Functional Proteomics and Systems Biology (FunPATh)—Center for Interdisciplinary Research and Innovation (CIRI-AUTH), GR-57001 Thessaloniki, Greece 3 Basic and Translational Research Unit, Special Unit for Biomedical Research and Education, School of Medicine, Aristotle University of Thessaloniki, GR-54124 Thessaloniki, Greece 4 Institute of Molecular Biology and Biotechnology, Foundation of Research and Technology, GR-70013 Heraklion, Greece * Correspondence: kpsatha@auth.gr (K.P.); aivaliotis@auth.gr (M.A.) Simple Summary: Despite continued efforts, the current status of knowledge in CLL molecular pathobiology, diagnosis, prognosis and treatment remains elusive and imprecise. Proteomics ap- proaches combined with advanced bioinformatics and drug repurposing promise to shed light on the complex proteome heterogeneity of CLL patients and mitigate, improve, or even eliminate the knowledge stagnation. In relation to this concept, this review presents a brief overview of all the available proteomics and drug repurposing studies in CLL and suggests the way such studies can be exploited to find effective therapeutic options combined with drug repurposing strategies to adopt and accost a more “precision medicine” spectrum. Citation: Mavridou, D.; Psatha, K.; Abstract: CLL is a hematological malignancy considered as the most frequent lymphoproliferative Aivaliotis, M. Proteomics and Drug disease in the western world. It is characterized by high molecular heterogeneity and despite the Repurposing in CLL towards available therapeutic options, there are many patient subgroups showing the insufficient effectiveness Precision Medicine.
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • Us 8530498 B1 3
    USOO853 0498B1 (12) UnitedO States Patent (10) Patent No.: US 8,530,498 B1 Zeldis (45) Date of Patent: *Sep. 10, 2013 (54) METHODS FORTREATING MULTIPLE 5,639,476 A 6/1997 OShlack et al. MYELOMAWITH 5,674,533 A 10, 1997 Santus et al. 3-(4-AMINO-1-OXO-1,3-DIHYDROISOINDOL- 395 A 22 N. 2-YL)PIPERIDINE-2,6-DIONE 5,731,325 A 3/1998 Andrulis, Jr. et al. 5,733,566 A 3, 1998 Lewis (71) Applicant: Celgene Corporation, Summit, NJ (US) 5,798.368 A 8, 1998 Muller et al. 5,874.448 A 2f1999 Muller et al. (72) Inventor: Jerome B. Zeldis, Princeton, NJ (US) 5,877,200 A 3, 1999 Muller 5,929,117 A 7/1999 Muller et al. 5,955,476 A 9, 1999 Muller et al. (73) Assignee: Celgene Corporation, Summit, NJ (US) 6,020,358 A 2/2000 Muller et al. - 6,071,948 A 6/2000 D'Amato (*) Notice: Subject to any disclaimer, the term of this 6,114,355 A 9, 2000 D'Amato patent is extended or adjusted under 35 SS f 1939. All et al. U.S.C. 154(b) by 0 days. 6,235,756 B1 5/2001 D'Amatoreen et al. This patent is Subject to a terminal dis- 6,281.230 B1 8/2001 Muller et al. claimer 6,316,471 B1 1 1/2001 Muller et al. 6,326,388 B1 12/2001 Man et al. 6,335,349 B1 1/2002 Muller et al. (21) Appl. No.: 13/858,708 6,380.239 B1 4/2002 Muller et al.
    [Show full text]
  • Overexpression of Salicylic Acid Carboxyl Methyltransferase (Cssamt1) Enhances Tolerance to Huanglongbing Disease in Wanjincheng Orange (Citrus Sinensis (L.) Osbeck)
    International Journal of Molecular Sciences Article Overexpression of Salicylic Acid Carboxyl Methyltransferase (CsSAMT1) Enhances Tolerance to Huanglongbing Disease in Wanjincheng Orange (Citrus sinensis (L.) Osbeck) Xiuping Zou * , Ke Zhao, Yunuo Liu, Meixia Du, Lin Zheng, Shuai Wang, Lanzhen Xu, Aihong Peng, Yongrui He, Qin Long and Shanchun Chen * Citrus Research Institute, Southwest University/Chinese Academy of Agricultural Sciences, Chongqing 400716, China; 15223141445@163.com (K.Z.); lynzyl0416@163.com (Y.L.); dmx18834196621@163.com (M.D.); zlin960911@163.com (L.Z.); wangshuai05072021@163.com (S.W.); lzx@cric.cn (L.X.); pengaihong@cric.cn (A.P.); heyongrui@cric.cn (Y.H.); longqin@circ.cn (Q.L.) * Correspondence: zouxiuping@cric.cn (X.Z.); chenshanchun@circ.cn (S.C.) Abstract: Citrus Huanglongbing (HLB) disease or citrus greening is caused by Candidatus Liberibacter asiaticus (Las) and is the most devastating disease in the global citrus industry. Salicylic acid (SA) plays a central role in regulating plant defenses against pathogenic attack. SA methyltransferase (SAMT) modulates SA homeostasis by converting SA to methyl salicylate (MeSA). Here, we report on the functions of the citrus SAMT (CsSAMT1) gene from HLB-susceptible Wanjincheng orange Citation: Zou, X.; Zhao, K.; Liu, Y.; (Citrus sinensis (L.) Osbeck) in plant defenses against Las infection. The CsSAMT1 cDNA was Du, M.; Zheng, L.; Wang, S.; Xu, L.; expressed in yeast. Using in vitro enzyme assays, yeast expressing CsSAMT1 was confirmed to Peng, A.; He, Y.; Long, Q.; et al. specifically catalyze the formation of MeSA using SA as a substrate. Transgenic Wanjincheng orange Overexpression of Salicylic Acid plants overexpressing CsSAMT1 had significantly increased levels of SA and MeSA compared to Carboxyl Methyltransferase wild-type controls.
    [Show full text]
  • And Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies
    pharmaceuticals Review Micro- and Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies Isabella Portugal 1, Sona Jain 1 , Patrícia Severino 1 and Ronny Priefer 2,* 1 Programa de Pós-Graduação em Biotecnologia Industrial, Universidade Tiradentes, Aracaju 49032-490, Brazil; isabella.martins@souunit.com.br (I.P.); sona.arun@souunit.com.br (S.J.); patricia.severino@souunit.com.br (P.S.) 2 Massachusetts College of Pharmacy and Health Sciences, University, Boston, MA 02115, USA * Correspondence: ronny.priefer@mcphs.edu Abstract: Photodynamic therapy is one of the more unique cancer treatment options available in today’s arsenal against this devastating disease. It has historically been explored in cutaneous lesions due to the possibility of focal/specific effects and minimization of adverse events. Advances in drug delivery have mostly been based on biomaterials, such as liposomal and hybrid lipoidal vesicles, nanoemulsions, microneedling, and laser-assisted photosensitizer delivery systems. This review summarizes the most promising approaches to enhancing the photosensitizers’ transdermal delivery efficacy for the photodynamic treatment for cutaneous pre-cancerous lesions and skin cancers. Additionally, discussions on strategies and advantages in these approaches, as well as summarized challenges, perspectives, and translational potential for future applications, will be discussed. Citation: Portugal, I.; Jain, S.; Severino, P.; Priefer, R. Micro- and Keywords: photodynamic therapy; drug delivery; transdermal; cutaneous; cancer Nano-Based Transdermal Delivery Systems of Photosensitizing Drugs for the Treatment of Cutaneous Malignancies. Pharmaceuticals 2021, 1. Introduction 14, 772. https://doi.org/10.3390/ ph14080772 In past decades, clinical demands for the utilization of photosensitizers (PSs) have increased with the advent of photodynamic therapy (PDT).
    [Show full text]
  • Prospects for NK Cell Therapy of Sarcoma
    cancers Review Prospects for NK Cell Therapy of Sarcoma Mieszko Lachota 1 , Marianna Vincenti 2 , Magdalena Winiarska 3, Kjetil Boye 4 , Radosław Zago˙zd˙zon 5,* and Karl-Johan Malmberg 2,6,* 1 Department of Clinical Immunology, Doctoral School, Medical University of Warsaw, 02-006 Warsaw, Poland; mieszko.lachota@wum.edu.pl 2 Department of Cancer Immunology, Institute for Cancer Research, Oslo University Hospital, 0310 Oslo, Norway; marianna.vincenti@rr-research.no 3 Department of Immunology, Medical University of Warsaw, 02-097 Warsaw, Poland; mwiniarska@wum.edu.pl 4 Department of Oncology, Oslo University Hospital, 0310 Oslo, Norway; kjetil.boye@rr-research.no 5 Department of Clinical Immunology, Medical University of Warsaw, 02-006 Warsaw, Poland 6 Center for Infectious Medicine, Department of Medicine Huddinge, Karolinska Institutet, Karolinska University Hospital, 141 86 Stockholm, Sweden * Correspondence: radoslaw.zagozdzon@wum.edu.pl (R.Z.); k.j.malmberg@medisin.uio.no (K.-J.M.) Received: 15 November 2020; Accepted: 9 December 2020; Published: 11 December 2020 Simple Summary: Sarcomas are a group of aggressive tumors originating from mesenchymal tissues. Patients with advanced disease have poor prognosis due to the ineffectiveness of current treatment protocols. A subset of lymphocytes called natural killer (NK) cells is capable of effective surveillance and clearance of sarcomas, constituting a promising tool for immunotherapeutic treatment. However, sarcomas can cause impairment in NK cell function, associated with enhanced tumor growth and dissemination. In this review, we discuss the molecular mechanisms of sarcoma-mediated suppression of NK cells and their implications for the design of novel NK cell-based immunotherapies against sarcoma.
    [Show full text]
  • Customs Tariff - Schedule
    CUSTOMS TARIFF - SCHEDULE 99 - i Chapter 99 SPECIAL CLASSIFICATION PROVISIONS - COMMERCIAL Notes. 1. The provisions of this Chapter are not subject to the rule of specificity in General Interpretative Rule 3 (a). 2. Goods which may be classified under the provisions of Chapter 99, if also eligible for classification under the provisions of Chapter 98, shall be classified in Chapter 98. 3. Goods may be classified under a tariff item in this Chapter and be entitled to the Most-Favoured-Nation Tariff or a preferential tariff rate of customs duty under this Chapter that applies to those goods according to the tariff treatment applicable to their country of origin only after classification under a tariff item in Chapters 1 to 97 has been determined and the conditions of any Chapter 99 provision and any applicable regulations or orders in relation thereto have been met. 4. The words and expressions used in this Chapter have the same meaning as in Chapters 1 to 97. Issued January 1, 2020 99 - 1 CUSTOMS TARIFF - SCHEDULE Tariff Unit of MFN Applicable SS Description of Goods Item Meas. Tariff Preferential Tariffs 9901.00.00 Articles and materials for use in the manufacture or repair of the Free CCCT, LDCT, GPT, UST, following to be employed in commercial fishing or the commercial MT, MUST, CIAT, CT, harvesting of marine plants: CRT, IT, NT, SLT, PT, COLT, JT, PAT, HNT, Artificial bait; KRT, CEUT, UAT, CPTPT: Free Carapace measures; Cordage, fishing lines (including marlines), rope and twine, of a circumference not exceeding 38 mm; Devices for keeping nets open; Fish hooks; Fishing nets and netting; Jiggers; Line floats; Lobster traps; Lures; Marker buoys of any material excluding wood; Net floats; Scallop drag nets; Spat collectors and collector holders; Swivels.
    [Show full text]
  • Treatment of Head and Neck Cancer with Photodynamic Therapy with Redaporfin: a Clinical Case Report
    Case Rep Oncol 2018;11:769–776 DOI: 10.1159/000493423 © 2018 The Author(s) Published online: November 27, 2018 Published by S. Karger AG, Basel www.karger.com/cro This article is licensed under the Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC) (http://www.karger.com/Services/OpenAccessLicense). Usage and distribution for commercial purposes requires written permission. Case Report Treatment of Head and Neck Cancer with Photodynamic Therapy with Redaporfin: A Clinical Case Report Lúcio Lara Santosa, b Júlio Oliveiraa Eurico Monteiroa Juliana Santosa Cristina Sarmentoc aPortuguese Institute of Oncology, Porto, Portugal; bExperimental Pathology and Therapeutics Group of Portuguese Institute of Oncology, Porto, Portugal; cUniversity Hospital of São João, Porto, Portugal Keywords Head and neck cancer · Immunotherapy · Immune checkpoint Inhibitor · Photodynamic therapy · Redaporfin Abstract Advanced head and neck squamous cell carcinoma, after locoregional treatment and multiple lines of systemic therapies, represents a great challenge to overcome acquired resistance. The present clinical case illustrates a successful treatment option and is the first to describe the use of photodynamic therapy (PDT) with Redaporfin, followed by immune checkpoint inhibition with an anti-PD1 antibody. This patient presented an extensive tumor in the mouth pavement progressing after surgery, radiotherapy, and multiple lines of systemic treatment. PDT with Redaporfin achieved the destruction of all visible tumor, and the sequential use of an immune checkpoint inhibitor allowed a sustained complete response. This case is an example of the effect of this therapeutic combination and may provide the basis for a new treatment modality. © 2018 The Author(s) Published by S. Karger AG, Basel Lúcio Lara Santos Instituto Português de Oncologia do Porto FG, EPE (IPO-Porto) Rua Dr.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19
    Preprints (www.preprints.org) | NOT PEER-REVIEWED | Posted: 20 April 2020 doi:10.20944/preprints202004.0367.v1 Potential Drug Candidates Underway Several Registered Clinical Trials for Battling COVID-19 Fahmida Begum Minaa, Md. Siddikur Rahman¥a, Sabuj Das¥a, Sumon Karmakarb, Mutasim Billahc* aDepartment of Genetic Engineering and Biotechnology, University of Rajshahi, Rajshahi-6205, Bangladesh bMolecular Biology and Protein Science Laboratory, University of Rajshahi, Rajshahi-6205, Bangladesh cProfessor Joarder DNA & Chromosome Research Laboratory, University of Rajshahi, Rajshahi-6205, Bangladesh *Corresponding Author: Mutasim Billah, Professor Joarder DNA & Chromosome Research Laboratory, University of Rajshahi, Rajshahi, Bangladesh Corresponding Author Mail: mutasimbillahshazu@gmail.com ¥Co-second author Abstract The emergence of new type of viral pneumonia cases in China, on December 31, 2019; identified as the cause of human coronavirus, labeled as "COVID-19," took a heavy toll of death and reported cases of infected people all over the world, with the potential to spread widely and rapidly, achieved worldwide prominence but arose without the procurement guidance. There is an immediate need for active intervention and fast drug discovery against the 2019-nCoV outbreak. Herein, the study provides numerous candidates of drugs (either alone or integrated with another drugs) which could prove to be effective against 2019- nCoV, are under different stages of clinical trials. This review will offer rapid identification of a number of repurposable drugs and potential drug combinations targeting 2019-nCoV and preferentially allow the international research community to evaluate the findings, to validate the efficacy of the proposed drugs in prospective trials and to lead potential clinical practices. Keywords: COVID-19; Drugs; 2019-nCoV; Clinical trials; SARS-CoV-2 Introduction A new type of viral pneumonia cases occurred in Wuhan, Hubei Province in China, on December 31, 2019; named "COVID-19" on January 12, 2020 by the World Health Organization (WHO) [1].
    [Show full text]
  • Supplementary Figure S1 Functional Characterisation of Snmp:GFP
    doi: 10.1038/nature06328 SUPPLEMENTARY INFORMATION SUPPLEMENTARY FIGURE LEGENDS Figure S1 | Functional characterisation of SNMP fusion proteins. Dose-response curve for cVA in Or67d neurons of wild-type (Berlin), SNMP mutant (Or67d- GAL4/+;SNMP1/SNMP2), SNMP:GFP rescue (Or67d-GAL4/UAS- SNMP:GFP;SNMP1/SNMP2) and YFP(1):Or83b/SNMP:YFP(2) rescue (Or67d:GAL4,UAS-YFP(1):Or83b/UAS-SNMP:YFP(2);SNMP1,Or83b2/SNMP2,Or83b1 ) animals. Mean responses are plotted (± s.e.m; wild-type n=47, SNMP mutant n=46, SNMP:GFP rescue n=20; YFP(1):Or83b/SNMP:YFP(2) rescue n=22; ≤4 sensilla/animal, mixed genders). Wild-type and SNMP:GFP rescue responses to cVA are not significantly different (ANOVA; p>0.1175). YFP(1):Or83b/SNMP:YFP(2) rescue responses to cVA are highly significantly different from SNMP mutants and from wild- type (ANOVA; p<0.0001), indicating partial rescue. Figure S2 | Cell type-specific rescue of SNMP expression. a, Immunostaining for mCD8:GFP (anti-GFP, green) and LUSH (magenta) in LUSH-GAL4/UAS-mCD8:GFP animals reveals faithful recapitulation of endogenous expression by the LUSH-GAL4 driver. b, Two-colour RNA in situ hybridisation for SNMP (green) and Or67d (magenta) in antennal sections of wild-type, Or67d neuron SNMP rescue (Or67d-GAL4/UAS- SNMP;SNMP1/SNMP2) and support cell SNMP rescue (LUSH-GAL4/UAS- SNMP;SNMP1/SNMP2) animals. www.nature.com/nature 1 Benton et al., Figure S1 ) -1 wild-type 120 SNMP:GFP rescue 80 YFP(1):Or83b/SNMP:YFP(2) rescue 40 Corrected response (spikes s 0 SNMP-/- 0 0.1 1 10 100 cVA (%) www.nature.com/nature 2 Benton
    [Show full text]
  • Stems for Nonproprietary Drug Names
    USAN STEM LIST STEM DEFINITION EXAMPLES -abine (see -arabine, -citabine) -ac anti-inflammatory agents (acetic acid derivatives) bromfenac dexpemedolac -acetam (see -racetam) -adol or analgesics (mixed opiate receptor agonists/ tazadolene -adol- antagonists) spiradolene levonantradol -adox antibacterials (quinoline dioxide derivatives) carbadox -afenone antiarrhythmics (propafenone derivatives) alprafenone diprafenonex -afil PDE5 inhibitors tadalafil -aj- antiarrhythmics (ajmaline derivatives) lorajmine -aldrate antacid aluminum salts magaldrate -algron alpha1 - and alpha2 - adrenoreceptor agonists dabuzalgron -alol combined alpha and beta blockers labetalol medroxalol -amidis antimyloidotics tafamidis -amivir (see -vir) -ampa ionotropic non-NMDA glutamate receptors (AMPA and/or KA receptors) subgroup: -ampanel antagonists becampanel -ampator modulators forampator -anib angiogenesis inhibitors pegaptanib cediranib 1 subgroup: -siranib siRNA bevasiranib -andr- androgens nandrolone -anserin serotonin 5-HT2 receptor antagonists altanserin tropanserin adatanserin -antel anthelmintics (undefined group) carbantel subgroup: -quantel 2-deoxoparaherquamide A derivatives derquantel -antrone antineoplastics; anthraquinone derivatives pixantrone -apsel P-selectin antagonists torapsel -arabine antineoplastics (arabinofuranosyl derivatives) fazarabine fludarabine aril-, -aril, -aril- antiviral (arildone derivatives) pleconaril arildone fosarilate -arit antirheumatics (lobenzarit type) lobenzarit clobuzarit -arol anticoagulants (dicumarol type) dicumarol
    [Show full text]